Clinical trials: Glial Fibrillary Acidic Protein
Donor Site Complication, Delirium
s100β, NSE n GFAP in Living Donor Hepatectomy and Delirium
The post-operative delirium picture is a serious and common complication seen after any major surgery, including hepatic resection.
- Conditions
- Donor Site Complication, Delirium, Uremic Encephalopathy, Neurologic Manifestations
- Trial name
- NCT04422925
- Testing
- Living Donor Hepatectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Kidney Transplant; Complications, Neurologic Manifestations
Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation
Uremic encephalopathy is an organic brain disorder may be frequently seen in patients with acute or chronic renal failure. Certain neurological symptoms can be found under clinical glomerular filtration rate of 15 ml/minutes.
- Conditions
- Kidney Transplant; Complications, Neurologic Manifestations, Uremic Encephalopathy
- Trial name
- NCT04042272
- Testing
- S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Anorexia Nervosa, Anorexia Nervosa Restricting Type
Novel Targetable BIOmarkers in ANorexia NervosA
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN).
- Trial name
- BIOANNA (NCT05885724)
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery.
- Conditions
- Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque
- Trial name
- VANGAS (NCT06211725)
- Where
- 2 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Neurofilament Light Chain, Glial Fibrillary Acidic Protein
Analysis of NfL and GFAP in Different Dietary Patterns
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet
- Trial name
- NCT07312994
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken